Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,520 Shares of Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Glaukos Trading Up 0.5 %

Shares of GKOS stock opened at $103.67 on Friday. Glaukos Co. has a 12-month low of $88.16 and a 12-month high of $163.71. The company has a market capitalization of $5.86 billion, a PE ratio of -36.12 and a beta of 0.99. The firm has a 50 day moving average price of $131.61 and a two-hundred day moving average price of $135.83. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. As a group, analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GKOS. Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. Stifel Nicolaus lifted their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average target price of $163.25.

Institutional Trading of Glaukos

Several hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming grew its position in shares of Glaukos by 2.3% during the 4th quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier’s stock worth $487,000 after purchasing an additional 72 shares in the last quarter. Quadrant Capital Group LLC grew its position in Glaukos by 3.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier’s stock worth $345,000 after buying an additional 73 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in Glaukos by 1.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 89 shares during the period. HighTower Advisors LLC raised its holdings in Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after acquiring an additional 91 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in shares of Glaukos by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.